This Killer Opioid Could Become a Weapon of Mass Destruction
(Bloomberg) -- It would take only 118 pounds of fentanyl to kill 25 million people.
That's how much of the powerful opioid painkiller Nebraska State Trooper Sam Mortensen found in April when he stopped a truck marked “U.S. Mail” swerving onto the shoulder along Interstate 80.
Rolling up the trailer door revealed an empty hold. But just below a refrigeration unit, behind a plastic panel secured with mismatched bolts, Mortensen found 42 brick-shaped packages, weighing 54 kilograms, full of fentanyl. The drug is so potent that even a small amount — the equivalent of a few grains of salt — can be lethal.
“Is that even believable? Can you even imagine?,” President Donald Trump said in October when Mortensen was honored at the White House for making one of the largest fentanyl seizures in U.S. history. The truck's two drivers were arrested. “Trooper Mortensen, that was a job well done.”
Fentanyl has emerged as the most dangerous of a group of drugs blamed for creating a U.S. public health crisis. American deaths linked to fentanyl grew more than 50 percent to 29,406 last year, from 19,413 in 2016, according to the National Institute on Drug Abuse (NIDA). Relatively easy to manufacture, the drug is turning up more on the streets as dealers strive to meet still-enormous demand for opioids in the U.S.
Fentanyl is ever-evolving as suppliers try to avoid detection and still boost the potency of the drug using what are called analogues — essentially chemical cousins.
“There's never been a drug like fentanyl before,” said Josh Bloom, senior director of chemical and pharmaceutical research at the American Council on Science and Health. “For street drugs, this absolutely destroys anything else in terms of lethality and danger.”
Fentanyl is 50 times more potent than heroin, with which it is often mixed. In its strongest form, called carfentanil, it is used legally as an elephant tranquilizer. Law enforcement officers and first responders have been warned to handle fentanyl with extreme caution; some have fallen seriously ill after getting it on their skin or clothing.
The fatal potential of even glancing contact with fentanyl is a major reason why national security experts are becoming alarmed at the prospect of it being used to sow terror. The drug is “a significant threat to national security,” Michael Morell, the former acting director of the Central Intelligence Agency under President Barack Obama, wrote last year. “It is a weapon of mass destruction.”
The use of fentanyl as a weapon isn't new. In 2002, 50 armed rebels held more than 800 hostages in a crowded theater in Moscow, demanding the withdrawal of Russian forces from Chechnya. After a few days, Russian forces used a gas, reported by state news agency Interfax to be fentanyl, to incapacitate the attackers, though more than 100 hostages were also killed.
As a tool of terror, the drug would work best in a closed space, said Daniel Gerstein, a senior policy researcher at Rand Corp. who served as acting undersecretary in the Department of Homeland Security's Science and Technology Directorate in the Obama administration. Open-air release likely wouldn't be as effective, as the drug could become too diluted, he said.
If ground-up fentanyl is placed on everyday objects, people could easily put their fingers in their mouths or rub their eyes and have a deadly reaction, said Bloom, the American Council on Science and Health official.
Containing a fentanyl attack would be difficult for police and emergency medical officials. Overdoses of the drug are hard to reverse with existing formulations of antidotes such as the Narcan nasal spray.
Narcan is carried by many police and paramedics, especially in areas hard-hit by the recent opioid epidemic. But people incapacitated by fentanyl frequently require multiple doses. Even some police and other emergency officials who've mistakenly ingested or absorbed the drug have needed multiple blasts of Narcan to be brought back.
Last year, police officer Chris Green made a traffic stop in East Liverpool, Ohio, and ended up with fentanyl powder on his shirt. After another officer pointed it out back at the station, Green brushed it off with his hand. Soon, paramedics were rushing him to the hospital.
“He realizes something ain't right,” said Police Chief John Lane. “He gets lightheaded.”
Green survived after being given four doses of Narcan. Though skin contact with fentanyl isn't typically deadly, Green had used sanitizer on his hands, which hastened the absorption of the fentanyl through his skin. A video distributed to law enforcement in August by U.S. Customs and Border Protection warns against using hand sanitizer and says those who have touched fentanyl shouldn't touch their eyes, nose or mouth.
The U.S. Biomedical Advanced Research and Development Authority, known as Barda, is tasked with developing medical countermeasures. In September, it penned a potential $4.6 million contract with Opiant Pharmaceuticals Inc. to produce a reliable single-dose fentanyl antidote.
“Fentanyl-based drugs have been used in conflicts in other countries, so we know it's possible, and we need to be ready to save lives and protect Americans from potential health security threats,” said Barda Director Rick Bright. He said repeat doses of naloxone, as Narcan is known generically, could be difficult to administer in a terror attack.
Opiant, based in Santa Monica, California, plans to test a nasal-spray version of a drug called nalmefene with the goal of counteracting fentanyl in one shot. In addition to the Barda deal, Opiant scored a $7.4 million grant from NIDA earlier this year to develop the new antidote. It is aiming to file for Food and Drug Administration approval in 2020.
“Nalmefene is five times more potent than naloxone,” Roger Crystal, chief executive officer of Opiant, said. “It's fighting fire with fire.”
The FDA approved injectable nalmefene, called Revex, in 1995, but Baxter International Inc. discontinued it in 2008. Crystal said the market has room for Narcan and nalmefene, but the more potent of the two will become dominant, especially with fentanyl becoming a central concern of drug enforcement. He thinks fentanyl production, currently focused in China, will increase in the U.S. as officials crack down on shipments at the border.
“It doesn't take much more than a half-competent chemist to be able to manufacture it,” Crystal said. “And it's cheaper to manufacture than heroin.”
Fentanyl is also extremely lucrative. One kilogram purchased from China for $3,000 to $5,000 can generate revenue of up to $1.5 million in the U.S., Paul Knierim, deputy chief of operations in the Office of Global Enforcement for the Drug Enforcement Administration, told a congressional panel in September. China agreed at a trade summit with the U.S. this month to regulate fentanyl as a controlled substance.
“Because we're in a fentanyl crisis, there's more fentanyl around, and for that reason the ability to get hold of it and getting it into the wrong hands isn't that hard,” Crystal said.
To contact the editor responsible for this story: Drew Armstrong at darmstrong17@bloomberg.net, Timothy AnnettMark Schoifet
©2018 Bloomberg L.P.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.